KLOWPeptide Dosage and Reconstitution Calculator

Easiest draw (2.5 mL BAC water → 20 mg GHK-Cu/mL): 0.1 mL (10 units on a U-100 syringe) delivers the 2 mg GHK-Cu target. Vial lasts 25 daily doses — well inside the 28-day refrigerated stability window.

Lower injection volume (1.25 mL BAC water → 40 mg GHK-Cu/mL): 0.05 mL (5 units) per dose. Smaller volume but tighter syringe read; also a more concentrated sting on injection.

Larger, more comfortable draw (5 mL BAC water → 10 mg GHK-Cu/mL): 0.2 mL (20 units) per dose. More volume to inject but very clean syringe read, and dilution meaningfully reduces the GHK-Cu sting.

Easiest draw (2 mL BAC water → 5 mg BPC-157/mL): 0.1 mL (10 units) delivers the 0.5 mg BPC-157 target. Vial lasts 20 daily doses.

Lower injection volume (1 mL BAC water → 10 mg BPC-157/mL): 0.05 mL (5 units) per dose. Tighter read, smallest volume, more concentrated GHK-Cu at the injection site.

Larger draw (4 mL BAC water → 2.5 mg BPC-157/mL): 0.2 mL (20 units) per dose. Cleaner syringe read; dilution also helps the GHK-Cu sting at this anchor's higher GHK-Cu payload (2.5 mg per dose).

For any target anchor dose D (mg) and anchor mass M in the vial (GHK-Cu = 50 mg, BPC-157 = 10 mg):

• Target 10 units (0.1 mL) per dose → V_water = (0.1 × M) / D mL
• Target 20 units (0.2 mL) per dose → V_water = (0.2 × M) / D mL
• Inverse: for any reconstitution volume V_water, each draw V_dose delivers D = (V_dose × M) / V_water mg of the anchor compound.

Use the KLOW Dosing Calculator for non-standard anchors or vial sizes — enter your target anchor dose and the calculator returns BAC water volume, draw units, and per-dose payload for all four peptides.

The most common side effect is GHK-Cu injection sting, caused by the copper-peptide complex¹ irritating subcutaneous tissue. It fades within 30–60 seconds and can be reduced by diluting with more BAC water, warming the vial to room temperature before drawing, injecting slowly, and rotating sites. Less common: mild fatigue for 12–24 hours after injection (more often with TB-4 than the other components), local redness or warmth if rotation is poor, and temporary mild headache in the first 1–2 weeks as protocols initiate. Persistent redness or warmth beyond 24 hours signals a local inflammatory reaction — rotate to a fresh site and dilute further. Contraindications: active malignancy, pregnancy, Wilson's disease or uncontrolled copper overload, and WADA-tested athletes (TB-4 is prohibited).

The sting comes from the copper-peptide complex in GHK-Cu irritating subcutaneous tissue on contact. It's normal, not a sign of contamination, and doesn't mean the vial is compromised. Four mitigations: reconstitute with more bacteriostatic water (3 mL instead of 2 mL reduces concentration-dependent sting), let the vial warm to room temperature for 10–15 minutes before drawing, inject slowly (a 5-second push hurts less than a 1-second push), and rotate injection sites. The sting typically fades within 30–60 seconds. If redness and warmth persist hours later, that's a local inflammatory reaction rather than normal GHK-Cu binding — rotate to a fresh site and dilute further.

Once daily. The blend is designed around daily subcutaneous dosing — GHK-Cu and KPV work well at daily intervals, and BPC-157's nanogram-threshold mechanism also supports daily. Some injury-focused users move to three times per week at higher per-dose volumes to better accommodate TB-4's bolus-driven mechanism, but this reduces the convenience that makes KLOW a practical alternative to individual-peptide protocols. The cleaner fix for injury use is daily KLOW plus standalone TB-500 2× weekly — keeping daily convenience while closing the TB-4 saturation gap.

Evening injection is the common default because GHK-Cu's collagen-gene regulation pairs with overnight dermal repair cycles, and KPV's anti-inflammatory action supports sleep-adjacent inflammation resolution. Morning is fine and produces comparable results; the timing choice mostly matters for consistency. Daily adherence matters more than time of day. If running the injury protocol with standalone TB-500, dose TB-500 in the morning on its scheduled days and keep KLOW in the evening — separating them by 6+ hours makes it easier to attribute any reaction to the right compound.

Skincare results typically appear within 3–4 weeks, with full effect by week 6–8. Injury recovery develops over 8–12 weeks: first pain and inflammation reductions by week 2, functional improvements by week 4–6, structural progress through week 8–12. If past week 6 with no noticeable change in injury recovery, the protocol is not working at its current dose — verify the vial contents against the Certificate of Analysis, check injection technique and storage, and consider adding standalone TB-500 2× weekly or switching to an individually-dosed injury protocol.

The blue color comes from copper in GHK-Cu binding as a copper-peptide complex. Blue is correct and expected for reconstituted KLOW. A colorless solution is more suspicious than a blue one — it may indicate missing or under-dosed GHK-Cu. The depth of blue varies with concentration: more BAC water produces a lighter tint, less water produces a more saturated blue. Either is fine as long as the color is present.

No. KLOW contains no GLP-1, GIP, or glucagon agonists, and none of the four peptides (BPC-157, TB-4, KPV, GHK-Cu) act on appetite, energy balance, or adipose signaling at meaningful levels. For weight loss, the relevant compounds are GLP-1-class drugs: semaglutide, tirzepatide, or retatrutide. If the underlying goal is both fat loss and tissue repair, run a GLP-1 for weight loss alongside KLOW for skin and tissue support — they operate on completely separate systems and don't interfere with each other.

Yes, and injury use is the second most common reason people run KLOW. The catch: stock KLOW's 10 mg TB-4 component runs at 15–25% of the dose needed to saturate intracellular actin reserves when anchored to BPC-157 daily dosing — meaning the cell-migration effect TB-4 is famous for doesn't fully fire. BPC-157 and KPV are in-range, and TB-4 still delivers systemic anti-fibrotic effects via its Ac-SDKP fragment, so KLOW heals injuries — just more slowly than optimally-dosed individual peptides. The standard fix: daily KLOW plus 3–5 mg standalone TB-500, 2× weekly, near the injury site. That single add-on closes the gap without abandoning KLOW's single-daily-injection convenience.

KLOW is sold by research-grade peptide suppliers, not pharmacies. Typical price runs $90–$150 per 80 mg vial. Before ordering, verify three things: a Certificate of Analysis from a third-party lab showing mass-spectrometry identity and purity for each of the four peptides at stated mg amounts (not in-house testing); the TB-4 / TB-500 mass spec (~4,900 Da = full-length TB-4, ~800 Da = the fragment); the stated ratio (standard is 50/10/10/10 = 80 mg total). Red flags: no CoA, "proprietary blend" without mg breakdown, colorless reconstituted solution (should be blue), marketing claims about FDA approval or clinical trials, pressure to buy bulk before seeing a CoA.

Yes, and this is common for injury protocols where repair tissue's metabolic demand is elevated. NAD+ at 150–250 mg, 3–5× per week, intramuscular, provides the cellular energy substrate that fibroblast collagen synthesis and angiogenesis run on. Do not co-inject NAD+ with KLOW — NAD+ is acidic (pH ~4) and will destabilize the peptide solution. Use a separate syringe and a different injection site, or schedule the two at least 30 minutes apart. NAD+ stings more than KLOW; slow injection and room-temperature solution both help.

Yes. KLOW pairs commonly with semaglutide, tirzepatide, or retatrutide during active weight-loss phases, specifically for skin and tissue support during rapid caloric deficit. GLP-1-driven fat loss can produce skin laxity, hair thinning, and slowed tissue recovery — KLOW's GHK-Cu and KPV support counteract these effects. The two operate on completely separate receptor systems and don't interfere pharmacologically. Inject KLOW and the GLP-1 on different days, or on the same day at separate sites.

For skincare: weeks 1–2, subtle texture change and the GHK-Cu "tight skin" feeling after injection. Weeks 3–4, visible tone evening and reduced reactive redness. Weeks 5–6, collagen-quality changes visible in under-eye area and fine lines. Weeks 7–8, full cycle effect. Learn more.

For injury recovery: weeks 1–2, reduced local inflammation and early warmth return to the injury site. Weeks 3–4, morning stiffness fades, range of motion improves. Weeks 5–8, load tolerance returns, tissue feels springy rather than stiff. With standalone TB-500 added, the TB-500 effect is most visible in week 5–8 when cell migration produces functional progress beyond what BPC-157 alone provides. Read about injury protocols.

Standard cycling is 6–8 weeks on, 2–4 weeks off for skincare, and 8–12 weeks on, 2–4 weeks off for injury recovery. Cycling preserves the distinction between active protocol and maintenance and gives a clean reference point for evaluating whether the approach is working. Long-term daily use is not harmful based on current safety data, but most users run KLOW in 6-to-12-week blocks two to four times per year. Step-down maintenance (every other day, or three times per week) is a common approach after the initial cycle.